Trials / Recruiting
RecruitingNCT06940102
Real-World Study on Nano-Crystalline Megestrol Acetate for Cachexia in TKI-Treated Advanced Digestive Tumors
A Multicenter, Real-World Study on Nano-Crystalline Megestrol Acetate for Cachexia in Patients With Advanced Digestive System Tumors Receiving TKI-Based Therapy
- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 120 (estimated)
- Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study is a prospective, observational clinical study aimed at evaluating the efficacy of Megestrol Acetate for cachexia in patients with advanced digestive system tumors receiving TKI-based therapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Nano-crystalline Megestrol Acetate Oral Suspension | Nano-crystalline Megestrol Acetate Oral Suspension, with a specification of 125 mg/mL, the study group takes 5 mL orally per day (625 mg/day) |
| DRUG | TKI-Based Therapy | TKI-Based Therapy |
Timeline
- Start date
- 2025-03-12
- Primary completion
- 2026-03-01
- Completion
- 2026-12-01
- First posted
- 2025-04-23
- Last updated
- 2025-04-23
Locations
2 sites across 1 country: China
Source: ClinicalTrials.gov record NCT06940102. Inclusion in this directory is not an endorsement.